Who is sponsoring NCT04626076?

NCT04626076 is sponsored by Certara.

What drugs are being tested in NCT04626076?

Interventions in NCT04626076: Comparative Observational Cohort Study.

What condition does NCT04626076 study?

NCT04626076 studies SARS-CoV Infection, Covid19.

Is NCT04626076 still recruiting?

NCT04626076 is currently completed. Last updated 4 April 2023.

Last reviewed 2023-04-04 · How we verify

NCT04626076

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

International Registry of Healthcare Workers Exposed to COVID-19 Patients (UNITY Global)

Completed Last updated 4 April 2023

What this trial tests

trial testing Comparative Observational Cohort Study in SARS-CoV Infection in 6,808 participants. Completed in 15 June 2022.

Timeline

3 August 2020

Primary endpoint
5 August 2021

15 June 2022

Quick facts

Lead sponsor	Certara
Status	Completed
Study type	OBSERVATIONAL
Enrollment	6,808
Start date	3 August 2020
Primary completion	5 August 2021
Estimated completion	15 June 2022
Sites	1 location across Pakistan

Drugs / interventions tested

Comparative Observational Cohort Study

Conditions studied

SARS-CoV Infection — all drugs for SARS-CoV Infection →
Covid19 — all drugs for Covid19 →

Sponsor

Certara — full company profile →

Who can join

18 and older, any sex, with SARS-CoV Infection or Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The International Registry of Healthcare Workers Exposed to COVID-19 Patients (UNITY Global), is an international registry of approximately 10,000 healthcare workers in low- and middle-income countries experiencing increasing numbers of COVID-19 cases and commensurate increased exposure to the SARS-CoV-2 virus among their healthcare worker populations.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for SARS-CoV Infection

Currently open trials in the same condition.

NCT05886816 — Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19 · Phase 2 · recruiting
NCT04802408 — SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial · Phase 2, PHASE3 · active not recruiting
NCT04815096 — Imaging Immune Activation in COVID-19 · Phase 2 · recruiting
NCT04747522 — Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Immune Kidney Transplant Study (COVID-19) · active not recruiting
NCT04579471 — Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04626076 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Certara
Last refreshed: 4 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04626076.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing